Sometimes when looking at insider buying the when is so important. ST Sensata Technologies Holding plc: this lurched up from $34 to $42 when the CEO was exited and a board seat went to an agitator... the insider buy comes after the move. Director of Sensata Technologies(ST)Ali Mirshekari purchased 268,310 shares of company stock at $39.64 per share for a total transaction amount of $10,636,265 ST- $42.61 0.27 (+0.64%)4:00 PM 05/13/24 NYSE | $USD | Post-Market: $42.62 +0.01 (+0.02%) 5:39 PM
I bought ST when you posted it, averaged up($38+). What do you think of IESC at $163, AXON at $300 and MSI $357?
Hahahahaha. Maybe you didn't.... but since you watch Cramer... one reader sent me an e-mail pointing out the fact that he had the CEO on Friday night. Coincidence? Give us a break Stoney. Your "stock of the week was a pure Mad Money Monday morning momo play. Hey good on ya for following Jim. He is smart. _______________________________ Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly By Julie Coleman,CNBC • Published May 10, 2024 • Updated on May 10, 2024 at 8:47 pm Source: Recursion Pharmaceuticals Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly " data-ellipsis="false"> In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to create new drugs. Recursion Pharmaceuticals is a clinical-stage biotech company that received a $50 million investment from Nvidia last summer. In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to make the process of developing drugs faster and less expensive. Recursion Pharmaceuticals is a clinical-stage biotech company that received a $50 million investment from Nvidia last summer. Gibson said Recursion is using this new technology to generate petabytes of data and then analyze it to "find new relationships across biology and chemistry" and create medicine, especially for rare diseases. "I think with clinical trials, there's still going to be a few years to get through the clinical trial space," Gibson said. "But, to find the drug and get it into the clinic, I think we can shorten that from five or six years and hundreds of millions of dollars into, perhaps, one or two years and just $10 million or $20 million." Recursion is currently developing a new drug to treat cerebral cavernous malformation, a neurovascular disease that Gibson said is not widely known but affects six times as many people in the U.S. than cystic fibrosis. Before Recursion's AI-focused approach, there wasn't a clear path toward making a drug to successfully tackle this disease, he said. The new treatment is almost done with its phase two trials. Gibson said he thinks the use of this new technology to map biology will be common in the biopharma industry in five or 10 years. ______________________________ Good Cramer repost! _________________________________________ As always.... at least my research is 10000% first-hand. The savant flagged GME at $20.50 this AM out of the 4 AM gate. The real readers, that use actual money, are up huge. Unfortunately Yahoo Finance doesn't enable you to see these things. Maybe get a real trading package? Then you can play with the retail big-dogs. Other than that... your posts are pretty pathetic and totally not original. Plus they lack any sort of cerebral dissection. For example this: What kind of stupid statement is this and how is this any different than any energy stock? Where's the thought process to justify such a rookie statement? It's not in the chart. And it's not in the fundy's. The only thing it has is a low float, hard to borrow, and no options.... Whatever.
There's dumb hillbillies with shotguns that throw out 10 "ideas"/day (and of course then claim them as their own if they happen to go up).... and then there's skilled snipers. The Stoney approach: Van's: Real research and homework are your friends Stoney. Not second hand pimps you get from notorious pump and dump sites. The readers want staying power. I have 50 emails to prove it.
He kinda looks like you too btw... at least going by that pic you posted that was allegedly you. We have a whole health food section here. Freddie is your friend. Especially if one is born with bad genetics. And we won't even go into savant skills. You missed out on those in the delivery room too.
YOUR MORNING MICRO DOSE - There's a little boy looking to get better who is very brave. He is the first child to receive Bluebird's gene therapy. (Science section NYT) - Boston Beer looks good. Boston Beer upgraded to Buy at Jefferies following distributor survey » -On Holding reports Q1 EPS CHF 0.33 vs. CHF 0.15 last year » 05:09 ONON / What the heck is CHF? -SE hit their earn! - I'm not seeing the news on the tape but I swear I saw (Bloomberg crawl) that SONY is doing a large stk split. Maybe 5-1. -Smart Sand (remember them) reports Q1 EPS (1c) vs. (9c) last year » 16:34 SND -QuickLogic reports Q1 non-GAAP EPS 12c vs. (9c) last year » 16:18 QUIK -Inovio reports Q1 EPS ($1.31), consensus ($1.00) » 16:08 INO -CareCloud reports Q1 adjusted EPS 1c, consensus (29c) » 07:14 CCLD -CareCloud sees FY24 revenue guidance $118M-$120M, consensus $117.72M » 07:14 CCLD CCLD CareCloud, Inc. $2.32 +1.06(+84.13%)<-- yikes! QUIK QuickLogic Corporation- Almost a gummy/ $12.560.08(+0.64%)3:59 PM 05/13/24 NASDAQ |$USD |Pre-Market:$13.00+0.44(+3.50%)7:00 AM
BLUE bluebird bio, Inc. $1.02-0.04(-3.77%)4:00 PM 05/13/24 NASDAQ |$USD |Pre-Market:$1.07+0.05(+4.90%)7:01 AM This is a $3 stk that sells for $1. Should they find success with this first patient the return will be huge.
Humacyte extends gains as FDA reviews blood vessel product NewsToday, 7:28 AM HUMA Humacyte, Inc. $5.480.78(+16.60%)4:00 PM 05/13/24 NASDAQ |$USD |Pre-Market:$5.80+0.32(+5.84%)7:10 AM What the FDA does is a crap shoot but this stock had insider selling at $2.78/ Niklason Laura E President, CEO and Director 2,000,000 shares sold<-------------------------------- BE CAREFUL! I could see a big rejection....